Conversations on 
Twitter :
 |
|
|
|
|
|
|
@FierceBiotech: J&J's diabetes drug passes FDA panel test despite safety concerns. Story | Follow @FierceBiotech
@RyanMFierce: Another failure for tivantinib $ARQL. Ph2 in colon cancer after PhIII fiasco in lung cancer last year. | Follow @RyanMFierce
> Sarepta ($SRPT) is considering its strategy for finding a global partner for its hot experimental DMD drug, eteplirsen. Article
> KaloBios started a Phase II study for a monoclonal antibody to fight infection in patients with cystic fibrosis. Release
@FierceMedDev: Bayer gains FDA nod for long-use IUD. Story | Follow @FierceMedDev
@MarkHFierce: A Swiss Dx company focused on nanotech brought in $3M in new Series A financing. Article | Follow @MarkHFierce
@DamianFierce: $LLY's jumping back on the companion diagnostics bandwagon with a new Dako partnership. Report | Follow @DamianFierce
> Medtronic hunts for expanded pacer indication with large study. Story
> As of July 1, Malaysia mandates device product registration. Item
Pharma News
@FiercePharma: Stada exec says board would entertain the right offer. Report | Follow @FiercePharma
@AlisonBFierce: Manufacturers already shipped more than 128M doses of flu vaccine--nearly 95% of the 135M doses made this season. More | Follow @AlisonBFierce
> Merck yanks cholesterol drug Tredaptive from market. News
> Hamburg: FDA has power to require abuse deterrence in painkillers. Item
> Drugmakers run short of Tamiflu, vaccine as flu bug bites hard. Story
And Finally… Merck ($MRK) took the cholesterol pill Tredaptive off shelves after the med failed in big Phase III study. Item